AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01309763 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD03
Description: s.c. injection
Study NCT01309763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE AD03 + Alum
Description: s.c. injection
Study NCT00704639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
Study NCT00704639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly intravenous carboplatin (AUC 2) for the duration of the RT
Study NCT00704639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended).
Study NCT03810586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of blood pressure
Description: Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
Study NCT03169062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gated Stationary Chest Tomosynthesis
Description: The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
Study NCT00506831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
Study NCT00860938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
Study NCT00860938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
Study NCT01126762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice regarding consumption of low mercury, high DHA fish
Study NCT01126762 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Advice regarding healthful diet during pregnancy, not focused on fish intake
Study NCT03133260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin
Description: Troponin will be measured before surgery and postoperative at days 1,2 and 3.
Study NCT03133260 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic acid
Description: 100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Study NCT03133260 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: 40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Study NCT01539239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Aqueous Implant
Description: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
Study NCT01539239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: A monofocal intraocular lens (IOL) placed during the cataract surgery.
Study NCT02407548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10 vitamin E softgel
Description: 4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
Study NCT02407548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10 softgel
Description: 4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
Study NCT02407548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: placebo softgel
Description: 4 placebo softgels per day. Keep normal lift style unchanged.
Study NCT02565160 — intervention group
Intervention type: PROCEDURE
Intervention: Intra-articular aspiration of Joint
Description: Procedural sampling of the joint for diagnostic purposes
Study NCT02565160 — intervention group
Intervention type: PROCEDURE
Intervention: Joint irrigation washout
Description: Procedural washout for treatment purposes
Study NCT02565160 — intervention group
Intervention type: PROCEDURE
Intervention: Total Joint Arthroplasty
Study NCT02565160 — intervention group
Intervention type: PROCEDURE
Intervention: Revision Joint Arthroplasty
Study NCT03077451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03077451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO
Study NCT04187872 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LITT + Pembrolizumab
Description: Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.
Study NCT03975140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypersensitive acupoint group
Description: The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
Study NCT03975140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyposensitive acupoint group
Description: The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
Study NCT03937154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
Study NCT03937154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00377962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
Study NCT00377962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid (MPA)/azathioprine (AZA)
Description: In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
Study NCT00959790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: 200 or 50 grams of vegetables daily for four weeks
Study NCT00959790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy restriction
Description: Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
Study NCT04709081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228
Description: ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
Study NCT04709081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).
Study NCT04709081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
Study NCT04709081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
Study NCT03442322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transdisciplinary approach
Description: This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
Study NCT03442322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary approach
Description: This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
Study NCT00377962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Description: Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
Study NCT02487355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 μg/ kg
Study NCT00377962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors (CNI)
Description: Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
Study NCT00377962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
Study NCT02744287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-601
Description: Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
Study NCT02744287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
Study NCT00529464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Spectroscopy
Description: Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
Study NCT00529464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: A standard colposcopy will be performed.
Study NCT00529464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LEEP Procedure
Description: A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
Study NCT01843075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injection
Study NCT04345874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition technical assistance
Description: Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
Study NCT00377962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
Study NCT02826057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted temperature management (33 degree Celsius)
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 MBq/kg Betalutin
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin
Study NCT02826057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (33 degree Celsius)
Study NCT01282814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride
Description: 150 mg Extended-Release Capsule
Study NCT01282814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® XR
Description: 150 mg Extended-Release Capsule
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 MBq/kg Betalutin
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 lilotomab
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 lilotomab
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01796171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mBq/kg Betalutin
Study NCT04307966 — intervention group
Intervention type: BEHAVIORAL
Intervention: The CIrCLE of Life Initiative
Description: HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
Study NCT03514147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;
Study NCT05172180 — intervention group
Intervention type: DRUG
Intervention: Reamberin
Description: the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
Study NCT03514147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;
Study NCT01335646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy
Description: lumbar discectomy within 1 month of randomization
Study NCT01335646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories
Description: Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
Study NCT02381158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate
Description: Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
Study NCT00262106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 2000/5
Description: Gel
Study NCT00262106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02809248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZES
Description: stent implantation (zotarolimus eluting stent)
Study NCT02809248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMS
Description: stent implantation (bare metal stent)
Study NCT02801357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lofexidine administration in subjects seeking buprenorphine dose reduction
Study NCT00005037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00005037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide capsule once a day for 42 days every 10 weeks.
Study NCT03037294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative protein supplementation
Description: Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
Study NCT04284644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction using propofol
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
Study NCT04284644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction using sevoflurane
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
Study NCT04284644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction using propofol and sevoflurane
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
Study NCT04063761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esophageal cooling device (Attune Medical, Chicago, IL)
Description: Prospective, single center pilot study
Study NCT00957372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablet, 800 mg or 1200 mg once daily
Study NCT00957372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (Part I)
Description: once daily placebo comparator
Study NCT05172180 — intervention group
Intervention type: DRUG
Intervention: Ringer's solution
Description: Ringer's solution at an average daily dose of 8.1 ml/kg/day
Study NCT02487355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium Sulphate 50 mg
Study NCT02487355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1ml/kg of 0.25%of bupivacaine
Study NCT02487355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine + Magnesium Sulphate + Bupivacaine
Description: Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
Study NCT03565653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary salt
Description: \~4,000 mg Na+/day
Study NCT02624414 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam® COLON 2 Capsule Endoscopy
Study NCT02867592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT02867592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO~Note: Capsule formulation (Cometriq) not used in this trial.
Study NCT02867592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03520647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
Study NCT03520647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells
Description: This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
Study NCT00957372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL - Open-label Extension (Part II)
Description: Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day